Rhenman & Partners Asset Management Ab Has Boosted Its Jazz Pharmaceuticals Plc (JAZZ) Stake; Argentiere Capital Ag Has Cut By $2.45 Million Its Gilead Sciences (GILD) Stake

December 7, 2017 - By Hazel Jackson

Argentiere Capital Ag decreased Gilead Sciences Inc (GILD) stake by 63.64% reported in 2017Q2 SEC filing. Argentiere Capital Ag sold 35,000 shares as Gilead Sciences Inc (GILD)’s stock declined 8.05%. The Argentiere Capital Ag holds 20,000 shares with $1.42 million value, down from 55,000 last quarter. Gilead Sciences Inc now has $94.88 billion valuation. The stock decreased 0.89% or $0.65 during the last trading session, reaching $72.64. About 4.44 million shares traded. Gilead Sciences, Inc. (NASDAQ:GILD) has declined 21.80% since December 7, 2016 and is downtrending. It has underperformed by 38.50% the S&P500.

Rhenman & Partners Asset Management Ab increased Jazz Pharmaceuticals Plc (JAZZ) stake by 40.95% reported in 2017Q2 SEC filing. Rhenman & Partners Asset Management Ab acquired 24,700 shares as Jazz Pharmaceuticals Plc (JAZZ)’s stock rose 8.72%. The Rhenman & Partners Asset Management Ab holds 85,020 shares with $13.22 million value, up from 60,320 last quarter. Jazz Pharmaceuticals Plc now has $8.08B valuation. The stock increased 0.84% or $1.12 during the last trading session, reaching $134.78. About 176,364 shares traded. Jazz Pharmaceuticals Public Limited Company (NASDAQ:JAZZ) has risen 1.25% since December 7, 2016 and is uptrending. It has underperformed by 15.45% the S&P500.

Since June 15, 2017, it had 0 insider purchases, and 1 insider sale for $30,130 activity. MILLER MICHAEL PATRICK also sold $30,130 worth of Jazz Pharmaceuticals Public Limited Company (NASDAQ:JAZZ) on Thursday, June 15.

Rhenman & Partners Asset Management Ab decreased Sage Therapeutics Inc (NASDAQ:SAGE) stake by 22,659 shares to 50,000 valued at $3.98M in 2017Q2. It also reduced Abiomed Inc (NASDAQ:ABMD) stake by 10,898 shares and now owns 106,150 shares. Edwards Lifesciences Corp (NYSE:EW) was reduced too.

Among 21 analysts covering Jazz Pharmaceuticals (NASDAQ:JAZZ), 16 have Buy rating, 0 Sell and 5 Hold. Therefore 76% are positive. Jazz Pharmaceuticals had 66 analyst reports since August 3, 2015 according to SRatingsIntel. Deutsche Bank maintained the shares of JAZZ in report on Wednesday, August 9 with “Buy” rating. The stock has “Hold” rating by Mizuho on Tuesday, December 5. The company was maintained on Tuesday, June 27 by RBC Capital Markets. FBR Capital maintained Jazz Pharmaceuticals Public Limited Company (NASDAQ:JAZZ) rating on Wednesday, November 8. FBR Capital has “Buy” rating and $206.0 target. The firm has “Neutral” rating by H.C. Wainwright given on Friday, November 10. The stock of Jazz Pharmaceuticals Public Limited Company (NASDAQ:JAZZ) earned “Buy” rating by SunTrust on Friday, November 3. BMO Capital Markets maintained the stock with “Buy” rating in Tuesday, September 19 report. The company was maintained on Monday, August 21 by Cowen & Co. The rating was maintained by Piper Jaffray with “Buy” on Friday, July 14. The firm has “Neutral” rating by Janney Capital given on Thursday, August 25.

Investors sentiment increased to 1.39 in Q2 2017. Its up 0.44, from 0.95 in 2017Q1. It increased, as 31 investors sold JAZZ shares while 79 reduced holdings. 51 funds opened positions while 102 raised stakes. 51.74 million shares or 0.45% less from 51.98 million shares in 2017Q1 were reported. Cambridge Invest Rech Advisors owns 1,462 shares for 0% of their portfolio. Prelude Capital Ltd Liability Corporation accumulated 0.25% or 16,759 shares. Atlantic Trust Grp Inc Inc Limited Liability Company, Georgia-based fund reported 61,815 shares. Rhenman Partners Asset Management Ab has 1.9% invested in Jazz Pharmaceuticals Public Limited Company (NASDAQ:JAZZ) for 85,020 shares. Qcm Cayman Limited has invested 0.54% in Jazz Pharmaceuticals Public Limited Company (NASDAQ:JAZZ). Moreover, Tower Cap Ltd Liability Corp (Trc) has 0.01% invested in Jazz Pharmaceuticals Public Limited Company (NASDAQ:JAZZ). First Personal Fincl Services invested in 0% or 67 shares. Commonwealth Bancorporation Of Aus invested in 909 shares or 0% of the stock. Sg Americas Secs Limited Liability owns 1,384 shares. Da Davidson And invested in 0% or 100 shares. The Maryland-based Proshare Advisors Ltd Com has invested 0.05% in Jazz Pharmaceuticals Public Limited Company (NASDAQ:JAZZ). Gargoyle Invest Advisor Ltd has 1,323 shares for 0.08% of their portfolio. Clarivest Asset Mgmt Limited Company has 3,325 shares for 0.01% of their portfolio. Aviva Public Ltd Com invested 0.03% of its portfolio in Jazz Pharmaceuticals Public Limited Company (NASDAQ:JAZZ). Citigroup Inc reported 0% stake.

Among 30 analysts covering Gilead Sciences (NASDAQ:GILD), 19 have Buy rating, 0 Sell and 11 Hold. Therefore 63% are positive. Gilead Sciences had 107 analyst reports since July 29, 2015 according to SRatingsIntel. The firm has “Outperform” rating given on Wednesday, February 3 by RBC Capital Markets. The stock has “Outperform” rating by Oppenheimer on Thursday, February 11. Mizuho initiated the stock with “Buy” rating in Tuesday, November 8 report. Stifel Nicolaus initiated the stock with “Buy” rating in Monday, November 14 report. The stock has “Equal-Weight” rating by Morgan Stanley on Friday, October 2. As per Wednesday, October 5, the company rating was maintained by Jefferies. BMO Capital Markets maintained the shares of GILD in report on Friday, October 27 with “Outperform” rating. The firm has “Strong Buy” rating given on Thursday, September 10 by Jyske Bank. The rating was maintained by Mizuho on Wednesday, November 8 with “Buy”. The firm earned “Buy” rating on Friday, April 29 by UBS.

Investors sentiment increased to 0.93 in 2017 Q2. Its up 0.02, from 0.91 in 2017Q1. It improved, as 78 investors sold GILD shares while 538 reduced holdings. 110 funds opened positions while 462 raised stakes. 938.32 million shares or 0.11% more from 937.32 million shares in 2017Q1 were reported. F&V Cap Mgmt Lc holds 79,570 shares. Atria Invs Ltd Llc stated it has 0.07% in Gilead Sciences, Inc. (NASDAQ:GILD). Horizon Kinetics Ltd Liability Company holds 0.02% or 9,400 shares in its portfolio. Northwestern Mutual Wealth, a Wisconsin-based fund reported 87,021 shares. Terril Brothers Incorporated reported 8,876 shares. Smith Chas P Assoc Pa Cpas holds 0.03% or 3,090 shares. 62,784 are owned by Trillium Asset Ltd Limited Liability Company. Tiemann Investment holds 2,865 shares or 0.18% of its portfolio. British Columbia – Canada-based Vertex One Asset Mgmt has invested 0.09% in Gilead Sciences, Inc. (NASDAQ:GILD). Truenorth invested 0.32% of its portfolio in Gilead Sciences, Inc. (NASDAQ:GILD). Parametric Portfolio Associates Limited Liability Corp holds 3.14M shares. The Michigan-based Arcadia Inv Management Corporation Mi has invested 0.02% in Gilead Sciences, Inc. (NASDAQ:GILD). Arete Wealth Advisors holds 0.3% or 9,416 shares. Fort Washington Advsr Oh reported 0.19% stake. Cap Guardian has 0.05% invested in Gilead Sciences, Inc. (NASDAQ:GILD) for 41,750 shares.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Twitter Auto Publish Powered By : XYZScripts.com